Half Year Results 

Spending doubles at Mereo BioPharma

Spending doubles at Mereo BioPharma

The decision to target areas of unmet medical need has proven sensible for Mereo BioPharma (MPH). The group’s new therapy for brittle bone disease – one of three drug programmes – was recently accepted onto the European Medicine Agency’s Adaptive Pathway, which means it is likely to be accelerated towards commercial launch if it achieves positive clinical results. The market for this illness may be small, but patients currently have no treatment option which means demand should be high.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now